1. Introduction {#sec1}
===============

Liver cancer is the second leading cause of cancer-related death worldwide, with approximately 850, 000 new cases occurring each year \[[@B1]\]. Among all the cases of liver cancer, hepatocellular carcinoma (HCC) accounts for about 90% \[[@B2]\]. Due to the poor prognosis of HCC, its mortality ranks third among all cancer types and shows an upward trend on a global scale \[[@B3], [@B4]\]. Compared with other prognostic factors, metastasis is one of the main reasons for cancer-related death \[[@B5]\]. Thereinto, lymph node metastasis (LNM) is common within extrahepatic metastases, second only to lung metastasis \[[@B6]\]. It was reported that the intraoperative detection rate of HCC LNM was 0.75%--7.5%, while the detection rate during autopsy was as high as 30.3% \[[@B6]\]. In the previous follow-up, we have found that around 10.3% of HCC patients after hepatectomy will develop LNM \[[@B7]\]. Although external beam radiotherapy is an effective means of treating HCC LNM, the prognosis of patients with LNM is worse than that of patients without LNM \[[@B8], [@B9]\].

Until now, the mechanisms underlying the development of LNM in HCC are poorly understood. Screening for biomarkers associated with HCC LNM can effectively identify high-risk patients, thereby taking steps to prevent disease progression after curative resection. In the previous studies, we have identified multiple biomarkers that are closely related to HCC LNM, such as hypoxia inducible factor-1*α* (HIF-1*α*), vascular endothelial growth factor (VEGF), and matrix metalloproteinase-2 (MMP-2)\[[@B7]\]. At this stage, we urgently hope to find out noninvasive and specific diagnostic markers to prevent the occurrence of HCC LNM.

Researches have found that lncRNAs are involved in multiple steps of cancer development, and they can be used as sensitive biomarkers to predict cancer metastasis \[[@B10], [@B11]\]. Moreover, lncRNAs have been identified in body fluids \[[@B12]--[@B14]\] and are emerging as novel biomarkers for disease and as targets for disease intervention \[[@B15], [@B16]\]. Based on the expression profile of serum lncRNAs in HCC LNM \[[@B17]\], we quantitatively analyzed the candidate lncRNAs in the serum samples of 242 patients and evaluated the correlation between the lncRNAs and HCC LNM. The biomarkers with potential predictive efficacy were finally screened out, and a prediction nomogram for HCC LNM based on serum lncRNAs was constructed for the first time in combination with clinicopathological parameters.

By applying prediction nomogram for noninvasive risk assessment, HCC patients at high risk for LNM could receive prophylactic radiotherapy towards regional lymph nodes, which could effectively reduce the incidence of LNM and prolong the overall survival of HCC patients \[[@B18]--[@B20]\]. Moreover, the abnormal expression and function of the HCC LNM-related serum lncRNA at cellular level may provide a basis for the mechanism study.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Serum Samples {#sec2.1}
-------------------------------

The enrolled patients received treatments at Zhongshan Hospital, Fudan University, from 2012 to 2016 and were pathologically diagnosed after surgery. The blood samples from the enrolled patients were collected at the time of surgery and the serums were subsequently extracted with centrifugation (1000×*g*, 10 min, 4°C). The serum samples were than stored at -80°C immediately. All the enrolled patients had complete medical history and clinicopathological data with follow-up and regular clinical examinations and were randomly assigned to the training and validation cohorts in a ratio of 2 : 1. The grouping and exclusion of the enrolled patients are shown in [Figure 1](#fig1){ref-type="fig"}. Among the included clinical indicators, the grade of tumor differentiation was determined using the Edmondson grading system and tumor size was measured depending on the maximum diameter of the tumor specimen. The vascular invasion was evaluated with microscopic examination of resected specimens.

All the procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee.

2.2. Follow-Up and Postoperative Treatments {#sec2.2}
-------------------------------------------

All the enrolled patients received routine follow-up every 3 months after surgery, which contains clinical examinations and medical history collection. Clinical examinations are composed of abdominal ultrasound examination, liver function test, and blood routine measurement, and all the examinations were performed by doctors who were blind to this study. When HCC LNM was suspected, CT scanning or MRI was carried out immediately for diagnosis. Once diagnosed with HCC LNM, patients were treated with radiotherapy for regional lymph nodes.

2.3. RNA Isolation and qRT-PCR {#sec2.3}
------------------------------

In order to relatively quantify the target lncRNAs, cel-mir-39-3p and GAPDH were used as the external and inner reference, respectively. Total RNAs were isolated from the serum samples using TRIzol LS reagent according to the manufacturer\'s instructions. Specifically, 0.75 ml TRIzol LS reagent (Life technologies, Carlsbad, CA, US) was added into 0.25 ml serum sample, and 50 fmol of cel-miR-39 was then added for normalization. Cell-derived RNAs were isolated using TRIzol reagent according to the manufacturer\'s instructions. After assessing the purity of the extracted total RNA, the process of reverse transcription was performed using Prime Script RT reagent Kit (Takara Bio, Shiga, Japan). The primer sequences were listed in [Table 1](#tab1){ref-type="table"}. QRT-PCR analyses were conducted using SYBR® Premix Ex Taq™ (Takara Bio, Shiga, Japan) in the 7500 Real-Time PCR System (Applied Biosystems). The relative expression levels of the candidate lncRNAs were normalized against reference standards by utilizing 2^−△Ct^ method.

2.4. Cell Culture {#sec2.4}
-----------------

Human hepatocyte cell line QSG-7701 and human HCC cell lines SMMC-7721, HuH-7, HepG2, MHCC-97H, MHCC-97L, and HCC-LM3 were cultured in DMEM containing 10% fetal bovine serum in a constant temperature incubator at 5% CO~2~, 37°C.

2.5. Fluorescence In Situ Hybridization {#sec2.5}
---------------------------------------

The fixed cells were infiltrated with citrate buffer at room temperature and placed in the cell punching solution for 10 minutes. The cells were immersed in prehybridized working solution at 42°C in the dark and incubated for 2 hours in a wet box. The sample was washed with 0.2×sodium citrate buffer and the hybridization working fluid containing lncRNA probe was then added for overnight rest. After removing the cover glass, the sample was washed at 37°C with 2×sodium citrate buffer, 0.2×sodium citrate buffer, and PBS-T solution. The nuclei were stained with DAPI for 10 minutes at room temperature and then encapsulated. Finally, the cells were observed and photographed by confocal laser scanning microscopy in a field in which the cell division phase was observed.

2.6. Lentivirus Transfection {#sec2.6}
----------------------------

An appropriate amount of lentivirus suspension (moi=30) was added at a cell density of 2×10^5^ /well and cultured at 5% CO~2~, 37°C. After 48 hours, the expression of fluorescent protein TurboGFP was detected under the microscope and the transfection efficiency was confirmed. The stable transfectant was screened by using 2 *μ*g/ml concentration of puromycin.

2.7. Wound Healing Assay {#sec2.7}
------------------------

The back side of the 6-well plate was marked with a horizontal line and uniformly plated at a cell density of 5×10^5^ per well. After cellular fusion, the vertical lines perpendicular to the marking lines were made with pipette tip in the cell distribution area. The 6-well plate was then washed three times with PBS buffer to ensure the complete removal of exfoliated cells, and the medium with low concentration of serum (2%) was also added. The treated 6-well plate was cultured in a constant temperature incubator at 5% CO~2~ and 37°C and photographed under a microscope at 0, 24, 48, and 72 hours.

2.8. Colony Formation Assay {#sec2.8}
---------------------------

Four hundred and eight hundred cells were laid in a 6 cm culture dish and cultured in a constant temperature incubator at 5% CO~2~ and 37°C. Two weeks later, visible clones were formed in the culture dish and more than 50 cells were found in most single clonal colonies. After removing the culture medium, PBS was gently washed along the medial wall of the dish three times, and 4% polyformaldehyde was used to fix the cells for 30 minutes. After one hour of continuous dyeing with crystal violet dye solution, rinse was performed along the side wall of the dish until clear dark blue colony spots appeared. The colonies containing more than 50 cells were counted three times in each dish, and the average value was taken as the final clone number. Quantitative analysis was carried out by GraghPad Prism software, and the clone formation rate was equal to the number of colonies/inoculated cells.

2.9. Statistical Analysis {#sec2.9}
-------------------------

By using SPSS 22.0 software (Chicago, IL, USA), GraphPad Prism 6.01 (La Jolla, CA, USA), Image J (National Institutes of Health, NIH), MedCalc Statistical Software 18.2.1 (Ostend, Belgium), and R software (version 3.2.3), all the statistical data were shown from at least three separate experiments. Specifically, the correlations between clinicopathological features and HCC LNM were analyzed by Pearson\'s correlation test and Fisher\'s exact test. Univariate analysis and multivariate Cox regression analysis (confounding variables that affect the regression coefficient by more than 10% were adjusted) were performed to determine independent risk factors of HCC LNM. The model was finally determined for nomogram with a backward step-down selection process. Estimates of the cutoff value and the model discriminatory ability were measured using time-depended ROC curves. Moreover, calibration curves originating from Hosmer-Lemeshow (H-L) test were applied for evaluation of the nomogram. The*P*\< 0.05 were normally considered statistically significant. Vascular invasion was also included as an independent risk factor with slightly higher*P* value (*P* = 0.055) and appropriate hazard ratio.

3. Results {#sec3}
==========

3.1. Patients\' Background Data {#sec3.1}
-------------------------------

Characteristics of all the enrolled HCC patients (157 in the training cohort and 85 in the validation cohort) used to establish a prediction model are summarized in [Table 2](#tab2){ref-type="table"}. Patients of the training cohort were observed until October 2016, and the median follow-up time was 55 months (range, 9-76 months). For the validation cohort, observation lasted until September 2016 and the median follow-up time was 45 months (range, 10-76 months). During the follow-up time, 20 patients (12.7%) in the training cohort and 9 patients (10.6%) in the validation cohort developed LNM.

3.2. Screening of Serum Biomarkers with Microarray {#sec3.2}
--------------------------------------------------

Through previous microarray analyses on serum samples, we have identified 235 lncRNAs that were differentially expressed among LNM group and non-LNM group as reported \[[@B17]\]. Among all the significant differential lncRNAs, five had fold change \> 2 and FDR values \< 0.05 with high expression abundance in serum samples. Lnc-GALR2-1:1 was downregulated with a FDR value of 0.034; ENST00000418803 was downregulated with a FDR value of 0.037; lnc-ZNF35-4:1 was downregulated with a FDR of 0.042; lnc-CAMKK2-3:2 was upregulated with a FDR of 0.037; and lnc-EPS15L1-2:1 was upregulated with a FDR of 0.037. We therefore conducted qRT-PCR to examine the expression of the candidate lncRNAs in serum samples from the training cohort and further evaluated the ability of these potential biomarkers for predicting HCC LNM.

3.3. Analysis of Serum Candidate lncRNAs Expression {#sec3.3}
---------------------------------------------------

With cel-mir-39-3p as an external reference, qRT-PCR was carried out to quantify the relative expression of the candidate lncRNAs in the serum samples. We first assessed the relevance between the serum lncRNA expression and diagnosis of HCC LNM based on the ROC curve and determined the cutoff value for judging lncRNA expression level simultaneously. Relative expressions of lnc-GALR2-1:1 and lnc-CAMKK2-3:2 in serum samples from the enrolled patients were verified to have no statistical significance for predicting HCC LNM. Besides, the remaining three lncRNAs were defined as high- or low-expression level based on the maximum value of Youden\'s index in the ROC analysis \[[@B21]\]. As showed in [Figure 2(a)](#fig2){ref-type="fig"}, the AUC of ENST00000418803, lnc-EPS15L1-2:1, and lnc-ZNF35-4:1 were 0.753 (95% CI: 0.678-0.819), 0.721 (95% CI: 0.644-0.790), and 0.766 (95% CI: 0.692-0.830), respectively, which indicated a considerable distinguishing power to HCC LNM. To further determine the diagnostic relevance between the above three lncRNAs and HCC LNM, Kaplan-Meier and Log-rank tests were performed among all patients from the cohorts as Figures [2(b)](#fig2){ref-type="fig"}, [2(c)](#fig2){ref-type="fig"}, and [2(d)](#fig2){ref-type="fig"} show. The distinctions between non-LNM and LNM groups in the training cohort divided by the optimum cutoff values were displayed in [Figure 3](#fig3){ref-type="fig"}. The low expression of ENST00000418803 and lnc-ZNF35-4:1 and the high expression of lnc-EPS15L1-2:1 showed significant correlations with the occurrence of LNM.

In the training cohort of 157 patients, low ENST00000418803 expression was found in 51 of 157 patients (32.5%), high lnc-EPS15L1-2:1 expression in 68 (43.3%), and low lnc-ZNF35-4:1 expression in 55 (35.0%). In the validation cohort, low ENST00000418803 expression was found in 30 of 85 patients (35.3%), high lnc-EPS15L1-2:1 expression in 33 (38.8%), and low lnc-ZNF35-4:1 expression in 27 (31.8%).

3.4. Significant Predictors of Lymph Node Metastasis in Hepatocellular Carcinoma {#sec3.4}
--------------------------------------------------------------------------------

For the training cohort, 19 clinicopathological features consisted of age, gender, HCV-Ab, HBsAg, a-fetoprotein, tumor differentiation, Child-Pugh score, intrahepatic metastasis, tumor size, vascular invasion, BCLC staging, ALT, *γ*-GT, liver cirrhosis, tumor number, and distant metastasis and the expression of the serum lncRNAs mentioned above was considered for the univariate analysis with Cox proportional hazards regression. The associations of the included variables with HCC LNM in the training cohort are summarized in [Table 3](#tab3){ref-type="table"}. Through univariate analysis, vascular invasion (*P*= 0.010), BCLC stage (*P*= 0.023), ENST00000418803 (*P*\< 0.001), lnc-EPS15L1-2:1 (*P*\< 0.001), and lnc-ZNF35-4:1 (*P*= 0.001) were selected to be significantly associated with LNM in HCC patients, whereas age (*P*= 0.286), gender (*P*= 0.187), HBsAg (*P*= 0.248), HCV-Ab (*P*= 0.997), a-fetoprotein (*P*= 0.539), tumor differentiation (*P*= 0.611), Child-Pugh score (*P*= 0.998), intrahepatic metastasis (*P*= 0.365), tumor size (*P*= 0.509), alanine aminotransferase (ALT) (*P*= 0.456), *γ*‐glutamyltransferase (*γ*-GT) (*P*= 0.878), liver cirrhosis (*P*= 0.756), tumor number (*P*= 0.585), and distant metastasis (*P*= 0.752) displayed no significant association with LNM. Statistically significant variables were further adopted for multivariate analysis. By adjusted multivariate analysis, the following five variables were found to be independent risk factors for LNM in HCC: vascular invasion (*P* = 0.055, HR: 2.5, 95% CI: 1.0 \~ 6.5), BCLC stage (*P*= 0.007, HR: 4.2, 95% CI: 1.5 \~ 12.0), ENST00000418803 (*P*\< 0.001, HR: 0.2, 95% CI: 0.1 \~ 0.5), lnc-EPS15L1-2:1 (*P*= 0.001, HR: 8.7, 95% CI: 2.5 \~ 30.6), and lnc-ZNF35-4:1 (*P*= 0.025, HR: 0.3, 95% CI: 0.1 \~ 0.9).

3.5. Construction of Prediction Nomogram for LNM in HCC {#sec3.5}
-------------------------------------------------------

As shown in [Figure 4](#fig4){ref-type="fig"}, the following five independent risk variables from multivariate cox regression analyses were selected into the visible nomogram to predict the risk of LNM: high lnc-EPS15L1-2:1 expression has the highest score of 100; low ENST00000418803 has the score of 73; low lnc-ZNF35-4:1 has the score of 51; BCLC stage; and vascular invasion was scored as 54 and 34, respectively. Considering the time distribution of LNM occurrence and the time-dependent AUC in the both cohorts, we determined the 29 months\' time (75% quartile) as an observation point, in which the nomogram has the best prediction performance and application value. The sum of score from all the included risk factors can further correspond to the risk assessment of LNM occurring within 29 months. The prediction nomogram demonstrated a good accuracy with stable and favourable time-dependent AUC among the training cohorts ([Figure 5(a)](#fig5){ref-type="fig"}). Calibration curves revealed a suitable calibration between the predictive LNM risk and the observed LNM risk as well ([Figure 5(c)](#fig5){ref-type="fig"}). Harrell\'s C-index of the stepwise selected model for LNM prediction was 0.89, which indicated a sound discrimination ability.

3.6. Validation for the Predictive Value of the lncRNA-Based Nomogram {#sec3.6}
---------------------------------------------------------------------

As [Figure 5(b)](#fig5){ref-type="fig"} shows, the trend of AUC was stable and satisfied in the interval of 15 to 31 months\' observation time point, which revealed a good prediction performance for LNM within the optimum time (29 months\' time). The calibration curve noted that the nomogram was well calibrated with a favorable fitting between the observed and predicted risk ([Figure 5(d)](#fig5){ref-type="fig"}). Furthermore, Harrell\'s C-index 0.85 of the model demonstrated good discrimination in the validation step.

3.7. Role of Lnc-EPS15L1-2:1 in Lymph Node Metastasis of HCC Cells {#sec3.7}
------------------------------------------------------------------

The aforementioned analyses showed that the high expression of serum lnc-EPS15L1-2:1 had a strong correlation with the occurrence of lymph node metastasis in HCC patients. However, the source of free lnc-EPS15L1-2:1 and the biological functions associated with HCC LNM remain unknown.

We performed qRT-PCR on the expression of lnc-EPS15L1-2:1 in human hepatocyte line QSG-7701 and human HCC cell lines SMMC-7721, Huh-7, HepG2, MHCC-97H, MHCC-97L, and HCC-LM3. Among these, SMMC-7721, HuH-7, MHCC-97H, and HCC-LM3 cell lines have high invasion and metastasis characteristics, which are highly malignant. On the contrary, HepG2 and MHCC-97L cell lines show low malignancy in invasion and metastasis. As shown in [Figure 6](#fig6){ref-type="fig"}, the expression of lnc-EPS15L1-2:1 in HCC cells was higher than that in normal hepatocytes and was significantly elevated in highly malignant cell lines. Fluorescence in situ hybridization (FISH) further confirmed the subcellular distribution of lnc-EPS15L1-2:1 which was mainly cytoplasmic ([Figure 7](#fig7){ref-type="fig"}).

The formation of tumor metastases depends on both high invasion and migration potential and strong clone-forming ability. Therefore, we performed wound healing assay and colony formation assay after the overexpression of SMMC-7721 cell line by lentiviral transfection. As shown in Figures [8](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}, lnc-EPS15L1-2:1 significantly enhanced the migration and clonality of HCC cells.

4. Discussion {#sec4}
=============

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. The incidence of LNM in extrahepatic metastases of HCC is approximately 33.8%, and the overall survival of untreated HCC patients with LNM is only about three months \[[@B6], [@B22]\]. Lymph node metastasis is a clear prognostic factor in treatments of cancer and has a significant impact on long-term survival of patients \[[@B23]\]. However, imaging technique is still not sensitive to the initial diagnosis of lymph node micrometastasis. It is necessary to build a specific model that predicts LNM risk in HCC patients for preventive intervention.

In general, the free nucleic acid in the circulation of tumor patients is mainly derived from the frequent apoptosis and necrosis of cells \[[@B24], [@B25]\]. Therefore, the abnormal expression of some cell-free RNA can partly reflect the expression profile of cancer cells, which is significantly related to the malignant process of cancer \[[@B26]\]. Aberrant expressions of lncRNAs have been reported to participate in diverse biological processes in cancer, including LNM \[[@B27]--[@B29]\]. Furthermore, lncRNAs are becoming a type of potential biomarkers for disease prediction \[[@B12], [@B30]\]. In the current study, we therefore sought to identify sensitive serum lncRNAs as noninvasive biomarkers to predict LNM in HCC.

We constructed and then validated a novel prediction nomogram based on three lncRNAs to predict LNM for HCC patients after hepatectomy. Our lncRNA-based nomogram incorporates the following five independent prognostic factors: BCLC stage, vascular invasion, low expression of ENST00000418803 and lnc-ZNF35-4:1, and high expression of lnc-EPS15L1-2:1. Using a linear predictor of 1.7 as the optimum cutoff value, 18.5% (n = 29) patients in the training cohort are identified as high-risk group, and 48.3% (n = 14) patients in the high-risk group developed LNM within the follow-up period. When applying the nomogram to the verification step, 14.1% (n = 12) patients in the validation group were allocated to the high-risk group, and 41.7% (n = 5) of whom were diagnosed with LNM. To our knowledge, this is the first report of serum lncRNA-based prediction nomogram in HCC, especially with respect to LNM. Utilizing this nomogram, posthepatectomy HCC patients can be accurately classified into groups with low and high risk of LNM at the early stage. The nomogram could serve as a valuable criterion for determining optimal treatment strategies for HCC patients.

We have two conjectures about the source of the lncRNAs that have potential predictive effects on HCC LNM. One possibility is that the abnormal cell-free lncRNAs may originate from the transformation process of premetastatic niches mediated by circulating tumor cells or tumor exosomes. NONCODE database displayed the notion that lnc-EPS15L1-2:1 are significantly highly expressed in lymph node compared with other tissues \[[@B31]\]. Another possibility is that changes in the expression profile of lncRNAs in tumor cells promote metastatic propensity. Cis analyses of protein-coding genes adjacent to the lncRNAs loci uncovered their possible roles in tumor malignant phenotype. Specifically, Kruppel-like factor 2 (KLF2), associated gene of lnc-EPS15L1-2:1 from Cis and Trans analyses, was reported as a terminal component of tumor proliferation and metastasis related pathway axis \[[@B32]--[@B34]\]. And ENST00000418803 associated gene Sad1 and UNC84 domain containing 2 (SUN2) act as novel suppressors in cancer \[[@B35], [@B36]\].

There is a strong correlation between the high expression of serum lnc-EPS15L1-2:1 and the occurrence of HCC LNM. Our further experiments confirmed that lnc-EPS15L1-2:1 is highly expressed in HCC cells compared with normal hepatocytes and is associated with the malignancy of HCC cells. Moreover, lnc-EPS15L1-2:1, mainly distributed in the cytoplasm, significantly promotes the migration and clonality of HCC cells. We are about to investigate the specific role of lnc-EPS15L1-2:1 in HCC LNM in the next stage of research.

Some limitations should also be acknowledged as follows. As it was a retrospective cohort study, and because of the limited quantity of patients involved, the results need to be further validated in a large scale of prospective study.

In conclusion, the nomogram based on serum ENST00000418803, lnc-ZNF35-4:1, lnc-EPS15L1-2:1, BCLC stage, and vascular invasion has good predictive performance for HCC LNM, and HCC patients at high risk of LNM may benefit from this. Moreover, as an independent risk factor, overexpression of lnc-EPS15L1-2:1 may mediate the occurrence of HCC LNM at the cellular level, which needs further verification. This study will provide new ideas for the clinical diagnosis and mechanism research of HCC LNM.
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![Patients\' grouping and exclusion.](BMRI2019-1710670.001){#fig1}

![*Screening and analyses of potential serum lncRNAs as biomarkers*. (a) Comparative ROC analysis of the five candidate lncRNAs screened by microarray analyses. (b) Kaplan-Meier and Log-rank analyses on difference in LNM cumulative incidence of patients with low or high expression of ENST00000418803. (c) Kaplan-Meier and Log-rank analyses on difference in LNM cumulative incidence of patients with low or high expression of lnc-EPS15L1-2:1. (d) Kaplan-Meier and Log-rank analyses on difference in LNM cumulative incidence of patients with low or high expression of lnc-ZNF35-4:1.](BMRI2019-1710670.002){#fig2}

![*The optimum cutoff value of the candidate lncRNAs for discrimination of expression levels among the training cohort*. (a) Relative expression of ENST00000418803 was distinguished by cutoff value 0.00216 as low or high expression. (b) Relative expression of lnc-EPS15L1-2:1 was distinguished by cutoff value 0.00246 as low or high expression. (c) Relative expression of lnc-ZNF35-4:1 was distinguished by cutoff value 0.00223 as low or high expression.](BMRI2019-1710670.003){#fig3}

![The visible nomogram based on lncRNAs and clinical indexes for predicting LNM in postoperative HCC patients.](BMRI2019-1710670.004){#fig4}

![*Time-dependent AUC and calibration tests of the nomogram among the training and validation cohorts*. (a) Time-dependent AUC of the nomogram among the training cohort. (b) Time-dependent AUC of the nomogram among the validation cohort. (c) Calibration curve of the nomogram among the training cohort. (d) Calibration curve of the nomogram among the validation cohort.](BMRI2019-1710670.005){#fig5}

![*Detection and analysis of lnc-EPS15L1-2:1 expression at the cellular level*. Lnc-EPS15L1-2:1 expression was abnormally elevated in HCC cells and was associated with high malignancy of HCC cells (*∗*:*P* \< 0.05; *∗∗∗∗*:*P* \< 0.0001).](BMRI2019-1710670.006){#fig6}

![*Determination of subcellular distribution of lnc-EPS15L1-2:1 using FISH*. Confocal images showed that most of lnc-EPS15L1-2:1 are distributed in the cytoplasm of HCC cells.](BMRI2019-1710670.007){#fig7}

![*Wound healing assay for SMMC-7721 cell line*. Comparison of migration degrees of HCC cells in the overexpression group (OE) and the control group (NC) at 0, 24, 48, and 72 hours (*∗*:*P*\< 0.05; *∗∗*:*P* \< 0.01; *∗∗∗*:*P* \< 0.001).](BMRI2019-1710670.008){#fig8}

![*Colony formation assay for SMMC-7721 cell line.* Comparison of clonogenicity degrees of HCC cells in the overexpression group (OE) and the control group (NC) at 400 and 800 inoculation densities (*∗∗∗*:*P* \< 0.001).](BMRI2019-1710670.009){#fig9}

###### 

Primer sequences designed for qRT-PCR.

  Gene ID           Forward primer                      Reverse primer                    Product length   Tm (°C)
  ----------------- ----------------------------------- --------------------------------- ---------------- ---------
  lnc-GALR2-1:1     5′-CTGAGCACCAAAAGTCTGGC-3′          5′-GCACTCCCATTGTTCGGGAT-3′        90               60
                                                                                                           
  ENST00000418803   5′-GCATAGGCATAAATTAGGATCTGGAGA-3′   5′-TGGAAGGGAGGGGAGTGGAT-3′        128              60
                                                                                                           
  lnc-ZNF35-4:1     5′-GAGTGAGTTTGTGGACCCAGATTTC-3′     5′-GGTCATGTTATATGCTTGCCTTCAG-3′   111              60
                                                                                                           
  lnc-EPS15L1-2:1   5′-TCCCCAACTTTCTGAGACTGT-3′         5′-AAGGAAGTGTGATCCGAGAGGT-3′      133              60
                                                                                                           
  lnc-CAMKK2-3:2    5′-GGATGCCCTAAAGGACTCCG-3′          5′-CCTCCAGATGGCCGTTTTCT-3′        94               60

###### 

Clinicopathological characteristics of the study cohorts.

  Variable                  Training cohort   Validation cohort                                    
  ------------------------- ----------------- ------------------- ---- ------------- ---- ---- --- ----------
  Age                                                                                               
   ≤ 51                     69                58                  11   0.339         39   33   6   0.290
   \> 51                    88                79                  9    46            43   3        
  Gender                                                                                            
   male                     131               112                 19   0.201         65   58   7   1
   female                   26                25                  1    20            18   2        
  HBsAg                                                                                             
   negative                 12                9                   3    0.183         6    6    0   1
   positive                 145               128                 17   79            70   9        
  HCV-Ab                                                                                            
   negative                 154               134                 20   1             81   75   6   0.003*∗*
   positive                 3                 3                   0    4             1    3        
  AFP, ng/mL                                                                                        
   ≤ 20                     44                37                  7    0.438         27   25   2   0.712
   \> 20                    113               100                 13   58            51   7        
  Tumor differentiation                                                                             
   I-II                     118               104                 14   0.584         68   61   7   1
   III-IV                   39                33                  6    17            15   2        
  Child-Pugh score                                                                                  
   A                        152               132                 20   1             83   75   8   0.202
   B                        5                 5                   0    2             1    1        
  Intrahepatic metastasis                                                                           
   no                       114               101                 13   0.428         66   61   5   0.108
   yes                      43                36                  7    19            15   4        
  Tumor size, cm                                                                                    
   ≤ 5                      89                79                  10   0.630         55   48   7   0.483
   \> 5                     68                58                  10   30            28   2        
  Vascular invasion                                                                                 
   no                       117               107                 10   0.012*∗*      59   54   5   0.446
   yes                      40                30                  10   26            22   4        
  BCLC stage                                                                                        
   0-A                      129               116                 13   0.054         74   69   5   0.014*∗*
   B-C                      28                21                  7    11            7    4        
  ALT, U/L                                                                                          
   ≤ 40                     74                63                  11   0.481         41   36   5   0.733
   \> 40                    83                74                  9    44            40   4        
  *γ*-GT, U/L                                                                                       
   ≤ 50                     35                30                  5    0.776         18   16   2   1
   \> 50                    122               107                 15   67            60   7        
  Liver cirrhosis                                                                                   
   no                       18                16                  2    1             9    9    0   0.588
   yes                      139               121                 18   76            67   9        
  Tumor number                                                                                      
   single                   108               93                  15   0.613         64   60   4   0.037*∗*
   multiple                 49                44                  5    21            16   5        
  Distant metastasis                                                                                
   no                       97                84                  13   0.810         55   53   2   0.008*∗*
   yes                      60                53                  7    30            23   7        
  ENST00000418803                                                                                  
   low expression           51                37                  14   \< 0.001*∗*   30   24   6   0.061
   high expression          106               100                 6    55            52   3        
  Lnc-EPS15L1-2:1                                                                                   
   low expression           89                86                  3    \< 0.001*∗*   52   49   3   0.084
   high expression          68                51                  17   33            27   6        
  Lnc-ZNF35-4:1                                                                                     
   low expression           55                41                  14   \< 0.001*∗*   27   20   7   0.004*∗*
   high expression          102               96                  6    58            56   2        

HBsAg: hepatitis B surface antigen; HCV-Ab: hepatitis C virus antibody; AFP: a-fetoprotein; ALT: alanine aminotransferase; *γ*-GT: *γ*-glutamyl transferase; BCLC stage: Barcelona Clinic Liver Cancer stage; *∗*: significance values.

###### 

Univariate and multivariate analyses of factors associated with lymph node metastasis of hepatocellular carcinoma among the training cohort.

  Clinicopathological factors   Univariate   Multivariate (Adjusted)                                  
  ----------------------------- ------------ ------------------------- ------------- ----------- ---- -------------
  Age                                                                                                  
   ≤ 51                         1.0                                    0.286         \-          \-   \-
   \> 51                        0.6          0.3\~1.5                  \-            \-               
  Gender                                                                                               
   male                         1.0                                    0.187         \-          \-   \-
   female                       3.9          0.5\~28.9                 \-            \-               
  HBsAg                                                                                                
   negative                     1.0                                    0.248         \-          \-   \-
   positive                     0.5          0.1\~1.7                  \-            \-               
  HCV-Ab                                                                                               
   negative                     1.0                                    0.997         \-          \-   \-
   positive                     0.0          0.0\~Inf                  \-            \-               
  AFP, ng/mL                                                                                           
   ≤ 20                         1.0                                    0.539         \-          \-   \-
   \> 20                        0.7          0.3\~1.9                  \-            \-               
  Tumor differentiation                                                                                
   I-II                         1.0                                    0.611         \-          \-   \-
   III-IV                       1.3          0.5\~3.3                  \-            \-               
  Child-Pugh score                                                                                     
   A                            1.0                                    0.998         \-          \-   \-
   B                            0.0          0.0\~Inf                  \-            \-               
  Intrahepatic metastasis                                                                              
   no                           1.0                                    0.365         \-          \-   \-
   yes                          1.5          0.6\~3.8                  \-            \-               
  Tumor size, cm                                                                                       
   ≤ 5                          1.0                                    0.509         \-          \-   \-
   \> 5                         1.3          0.6\~3.2                  \-            \-               
  Vascular invasion                                                                                    
   no                           1.0                                    0.010*∗*      1.0              0.055
   yes                          3.2          1.3\~7.6                  2.5           1.0\~6.5         
  BCLC stage                                                                                           
   0-A                          1.0                                    0.023*∗*      1.0              0.007*∗*
   B-C                          2.9          1.2\~7.3                  4.2           1.5\~12.0        
  ALT, U/L                                                                                             
   ≤ 40                         1.0                                    0.456         \-          \-   \-
   \> 40                        0.7          0.3\~1.7                  \-            \-               
  *γ*-GT, U/L                                                                                          
   ≤ 50                         1.0                                    0.878         \-          \-   \-
   \> 50                        0.9          0.3\~2.5                  \-            \-               
  Liver cirrhosis                                                                                      
   no                           1.0                                    0.756         \-          \-   \-
   yes                          1.3          0.3\~5.4                  \-            \-               
  Tumor number                                                                                         
   single                       1.0                                    0.585         \-          \-   \-
   multiple                     0.8          0.3\~2.1                  \-            \-               
  Distant metastasis                                                                                   
   no                           1.0                                    0.752         \-          \-   \-
   yes                          0.9          0.3\~2.2                  \-            \-               
  ENST00000418803                                                                                     
   low expression               1.0                                    \< 0.001*∗*   1.0              \< 0.001*∗*
   high expression              0.2          0.1\~0.5                  0.2           0.1\~0.5         
  Lnc-EPS15L1-2:1                                                                                      
   low expression               1.0                                    \< 0.001*∗*   1.0              0.001*∗*
   high expression              9            2.6\~30.7                 8.7           2.5\~30.6        
  Lnc-ZNF35-4:1                                                                                        
   low expression               1.0                                    0.001*∗*      1.0              0.025*∗*
   high expression              0.2          0.1\~0.5                  0.3           0.1\~0.9         

HBsAg: hepatitis B surface antigen; HCV-Ab: hepatitis C virus antibody; AFP: a-fetoprotein; ALT: alanine aminotransferase; *γ*-GT: *γ*-glutamyl transferase; BCLC stage: Barcelona Clinic Liver Cancer stage; CI, confidence interval; *∗*: significance values.

[^1]: Guest Editor: Bin Duan
